Molecular imaging with PET: New insights into the molecular basis of health and disease

MedicaMundi

Volumn 47, Issue 1, 2003, Pages 18-27

  Hamisch Y ^a  

^a PHILIPS HEALTHCARE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 58349119159     PISSN: 00257664     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (36)

1. Martinez-Lazaro R, Cortes-Blanco A, Zhuang HM, Alavi A. Diagnostic Performance of Whole Body FDG-PET and CT Imaging in Malignant Lymphomas [Abstract]. J Nucl Med. 2000; 41: 277 pp.
2. Lang O, Doerr U, Schneider K, Hagen R, Bihl H. Cervical Lymph Node Staging in Patients with Head and Neck Cancer: A Comparison Between 18F-FDG-PET and Ultrasound [Abstract]. J Nucl Med. 2000; 41: 32 pp.
3. Kubik-Huch RA, Dörffler W, Von Schulthess GK et al. Value of (18F)-FDG Positron Emission Tomography, Computed Tomography, and Magnetic Resonance Imaging in Diagnosing Primary and Recurrent Ovarian Carcinoma. Eur Radiol. 2000; 10: 761-767.
4. Adams S, Baum R, Stuckensen T, Bitter K, Hör G. Prospective Comparison of 18F-FDG PET with Conventional Imaging Modalities (CT, MRI, US) in Lymph Node Staging of Head and Neck Cancer. Eur J Nucl Med. 1998; 25: 1255-1260.
5. Delbeke D, Martin WH, Sandler MP, Chapman WC, Wright JK, Prinson CW. Evaluation of Benign versus Malignant Hepatic Lesions with Positron Emission Tomography. Arch Surg. 1998; 133: 510-516.
6. Blasberg RG, Gelovani J. Molecular-Genetic Imaging: A Nuclear Medicine Based Perspective. Molecular Imaging 2002; 1 (3): 280-300.
7. For Example: Clarke R, Dickson RB, Brunner N. The Process of Malignant Progression in Human Breast Cancer. Ann Oncol 1990; 1: 401-407.
8. Hämisch Y. Positronen-Emissions-Tomographie (PET) - funktionale Diagnostik und Therapie-management in der modernen Medizin: ein technologischer Überblick. In: Kramme R (Ed.) Medizintechnik-Verfahren, Systeme und Informationsverarbeitung, ein anwenderorientierter Querschnitt für die Praxis. Springer, Heidelberg, 2002; 2: 335 pp. (Also published in English).
9. Warburg O. The Metabolism of Tumors. Richard R Smith, New York 1931: 129-169.
10. Chaiken L, Rege S, Hoh C et al. Positron Emission Tomography with Fluorodeoxyglucose to Evaluate Tumor Response and Control after Radiation Therapy. Int J Radiat Oncol Biol Phys, 1993; 27: 455-464.
11. Couper GW, Mcateer D, Wallis F et al. Detection of Response to Chemotherapy using Positron Emission Tomography in Patients with Oesophageal and Gastric Cancer. Br J Surg. 1998; 85: 1403-1406.
12. Schelling M, Avril N, Nährig J et al. Positron Emission Tomography using [18F] Fluorodeoxyglucose for Monitoring Primary Chemotherapy in Breast Cancer. J Clin Oncol. 2000; 18: 1689-1695.
13. Weber WA, Ott K, Becker K et al. Prediction of Response to Preoperative Chemotherapy in Adenocarcinomas of the Esophagogastric Junction by Metabolic Imaging. J. Clin. Oncol. 2001; 19 (12): 3058-3065.
14. Chacko TK, Zhuang H, Stevenson K, Moussavian B, Alavi A. Importance of Location of FDG Uptake in Periprosthetic Infection in Painful Hip Prostheses. Nuclear Medicine Communication 2002; 23 (9): 851-855.
15. Stopeck AT, Hersh EM, Apkoriaye ET et al. Phase I Study of Direct Gene Transfer of an Allogeneic Histocompatibility Antigen, HLA-B7, in Patients with Metastatic Melanoma. J Clin Oncol 1997; 15 (1): 341-349.
16. Izquierdo M, Cortes ML, Martin V et al. Gene Therapy in Brain Tumours: Implications of the Size of Glioblastoma on its Curability. Acta Neurochir Suppl 1997; 68: 111-117.
17. Roth JA, Swisher SG, Merritt JA et al. Gene Therapy for Non-Small Cell Lung Cancer: A Preliminary Report of a Phase I Trial of Adenoviral P53 Gene Replacement. Semin Oncol 1998 Jun; 25 (3 Suppl 8): 33-37.
18. Gambhir SS, Barrio JR, Wu L et al. Imaging of Adenoviral-Directed Herpes Simplex Virus Type 1 Thymidine Kinase Reporter Gene Expression in Mice with Radiolabeled Ganciclovir. J Nucl Med 1998; 39: 2003-2011.
19. Gambhir SS, Barrio JR, Phelps ME et al. Imaging Adenoviral-Directed Reporter Gene Expression in Living Animals with Positron Emission Tomography. Proc Natl Acad Sci USA 1999; 96: 2333-2338.
20. Gambhir SS, Bauer E, Black ME et al. Mutant Herpes Simplex Virus Type 1 Thymidine Kinase Reporter Gene shows Improved Sensitivity for Imaging Reporter Gene Expression with Positron Emission Tomography. Proc Natl Acad Sci USA 1999; 97: 2785-2790.
21. Shields AF, Grierson JR, Dohmen BM et al. Imaging Proliferation In Vivo with [F-18]FLT and Positron Emission Tomography (PET). Nature Medicine 1998; 4 (11): 1334-1336.
22. Patt M, Kumar P, Wiebe LI, Machulla HJ. [18F] Fluorazomycinarabinosid (F-AZA), ein neuer Radiotracer zur bestimmung von Gewebehypoxien. Nuklearmedizin 1999; 38 (A22).
23. 18F] FLT. J Nucl. Med. 2000; 41 (5): 74 pp.
24. 18F]FDG for Tumor PET: First Results of a Comparative Study. J Nucl Med. 2000; 41 (5): 84 pp.
25. 18F]Fluoromisonidazole Uptake on Oxygen Delivery and Tissue Oxygenation in the Porcine Liver. Nucl Med Biol. 2000; 27: 693-700.
26. Paulsen F, Alber M, Eschmann SM et al. Hypoxia Image-Guided Intensity Modulated Radiation Treatment Planning of Head and Neck Tumors. Int J Rad Oncol Biol Phys 2002; 54 (2): Supplement.
27. Haseman MK, Reed NL, Rosenthal SA. Monoclonal Antibody Imaging of Occult Prostate Cancer in Patients with Elevated Prostate Specific Antigen. Positron Emission Tomography and Biopsy Correlation. Clin Nucl Med. 1996; 21: 704-713.
28. Goldberg D. The Role of Radiolabeled Antibodies in the Treatment of Non-Hodgkins Lymphoma: The Coming Age of Radioimmunotherapy. Crit. Rev Oncol Hematol 2001; 39: 195-201.
29. O'Connor MK, Kvols LK, Brown ML et al. Dosimetry and Biodistribution of an Iodine-123-Labeled Somatostatin Analog in Patients with Neuroendocrine Tumors. J Nucl Med. 1992; 33 (9): 1613-1619.
30. Krenning EP et al. Localisation of Endocrine-Related Tumours with Radioiodinated Analogue of Somatostatin. Lancet. 1989; 1 (8632): 242-244.
31. Bakker WH, Krenning EP, Breenan WA et al. In Vivo use of a Radioiodinated Somatostatin Analogue: Dynamics, Metabolism and Binding Somatostatin Receptor-Positive Tumors in Man. JNM 1991; 32: 1184-1189.
32. Hofmann M, Maecke H, Borner R et al. Biokinetics and Imaging with the Somatostatin Receptor PET Radio-ligand. Eur J Nucl Med. 2001; 28 (12): 1751-1757.
33. Wester HJ, Schottelius M, Scheidhauer K et al. PET Imaging of Somatostatin Receptors: Design, Synthesis and Preclinical Evaluation of a Novel 18F-Labelled, Carbohydrated Analogue of Octreotide. Eur J Nucl Med Mol Imaging. 2003 Jan; 30 (1): 117-122.
34. 11C] Carfentanil PET Study. J Nucl Med 2001; 42 (5): 107 pp.
35. Valette H, Dollé F, Guenther I et al. In Vivo Quantification of Myocardial Dihydropyridine Binding Sites: A PET Study in Dogs. J Nucl Med. 2002; 43 (9): 1227-1233.
36. 100mIn]-DTPA-D-Phe-Octreotide for Imaging of Neuroendocrine Tumors with PET. J Nucl Med. 2002; 43 (10): 1391-1397.